Form 4: AEON Biopharma Director Jost Fischer Granted Over 300,000 Restricted Stock Units

AEON Biopharma, Inc. Director Jost Fischer was granted 308,641 Restricted Stock Units (RSUs) as part of his compensation, which will vest fully on May 21, 2026.

Summary

• Jost Fischer, a Director of AEON Biopharma, Inc. (AEON), reported the acquisition of 308,641 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of AEON's Class A Common Stock on the applicable vesting date.
• All 308,641 RSUs are scheduled to vest in full on the one-year anniversary of the grant date, specifically May 21, 2026.
• Following this transaction, Jost Fischer beneficially owns 308,641 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive event as it aligns the director's interests with those of the shareholders, promoting long-term commitment and performance. It is a standard compensation practice and does not indicate any negative underlying issues.

Positives

• The grant of Restricted Stock Units to Director Jost Fischer aligns his financial interests with the long-term performance of AEON Biopharma, Inc. and its shareholders.
• Equity compensation is a standard practice that can incentivize management and directors to contribute to the company's growth and value creation.

Future Outlook

This Form 4 filing pertains to an equity grant and does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

The grant of Restricted Stock Units to a director is a common form of equity-based compensation across various industries, including biotechnology and pharmaceuticals. It is a standard mechanism used by companies to attract, retain, and incentivize key personnel by aligning their compensation with the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a widely accepted practice in the biotechnology and pharmaceutical sectors, consistent with compensation strategies employed by companies like Amgen, Gilead Sciences, or Biogen, which frequently utilize similar long-term incentive plans to align executive and director interests with shareholder value.
• The specific size of the RSU grant (308,641 units) for a director would typically be evaluated against peer group compensation data for companies of similar market capitalization, stage of development, and industry within the biotech space, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Jost Fischer, a Director of AEON Biopharma, Inc., constitutes a related party transaction as it involves compensation provided to an insider of the company.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be viewed positively as it aligns the director's financial incentives with the company's stock performance, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall employee morale and retention strategies.

Next Steps

• The Restricted Stock Units will vest on May 21, 2026, at which point they will be settled in cash based on the fair market value of AEON's Class A Common Stock.

Key Dates

Keywords

AEON Biopharma, AEON, Form 4, Insider Transaction, Restricted Stock Units, RSU, Jost Fischer, Director, Equity Compensation, Beneficial Ownership